The Endocrine Society
Patients prefer combined therapy for hypothyroidism, but data reveal few added benefits
BOSTON — Most adults with hypothyroidism prefer combination therapy with liothyronine plus levothyroxine over levothyroxine alone, but most trials find combination therapy provides limited added benefit, according to two speakers.
Advances in AI could improve disease prediction, reduce provider stress
BOSTON — Explainable AI and systems that help providers with day-to-day tasks will allow experts to conduct more advanced research and make impactful changes in clinical care, according to two speakers at ENDO 2024.
Health effects of PFAS exposure through breastmilk largely unknown
BOSTON — Women exposed to a class of endocrine-disrupting chemicals known as PFAS may be more likely to struggle with breastfeeding, whereas the health effects of infant exposure to PFAS via breastmilk remain unknown, a speaker said.
‘This is going to take all of us’: Creative partnerships can reduce cardiometabolic risk
BOSTON — Lowering cardiovascular risk for people with type 2 diabetes requires effort from far beyond the clinician’s office, leveraging creative community partnerships that address social determinants of health, according to a speaker.
New data unraveling role of the gut microbiome in PCOS
BOSTON — Evidence suggests hyperandrogenism is associated with changes in the gut microbiome in women with polycystic ovary syndrome and the gut microbiome may play a causal role in PCOS metabolic dysregulation, according to a speaker.
Hot flash severity may predict metabolic-associated liver disease
BOSTON — Midlife women reporting bothersome hot flashes are more likely to receive a diagnosis of metabolic dysfunction-associated steatotic liver disease regardless of hormone therapy use, according to a speaker.
Primary ovarian insufficiency, reproductive cancers may be linked across generations
BOSTON — People with primary ovarian insufficiency have higher risk for breast cancer and borderline increased risk for ovarian cancer compared with the general population, and risks for some cancers extend to their relatives, data show.
VIDEO: Data shed new light on treatments for acromegaly, Cushing’s disease
BOSTON — In this video exclusive, Maria Fleseriu, MD, FACE, discusses some of the top adrenal and pituitary news from ENDO 2024.
Osilodrostat improves comorbid hypertension, diabetes for adults with Cushing’s disease
BOSTON — Long-term osilodrostat therapy may improve symptoms of comorbid cardiometabolic disorders such as hypertension and diabetes for adults with Cushing’s disease, according to data presented at ENDO 2024.
EDC exposures for reproductive-aged women tied to socioeconomic status
BOSTON — Pregnant and reproductive-aged women have had recent declines in exposure to most endocrine-disrupting chemicals, though women with a lower socioeconomic status are exposed to higher chemical levels, according to a speaker.